Stock Events

Stock Events

Atrium Therapeutics 

$14.60
63
+$0.00+0% 09:42 Today

Statistics

Day High
14.62
Day Low
14.57
52W High
16.77
52W Low
11.13
Volume
11,576
Avg. Volume
-
Mkt Cap
249.74M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.42
-1.15
-0.88
-0.61
Expected EPS
-0.866168
Actual EPS
N/A

Financials

-3,650.39%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
37.51MRevenue
-1.37BNet Income

Analyst Ratings

25.00Average Price Target
The highest estimate is 25.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNA. It's not an investment recommendation.
Amazon
18
AMZN
Microsoft
17
MSFT
NVIDIA
14
NVDA
Apple
13
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-targeted therapeutics, particularly for rare neuromuscular diseases, directly competing with Avidity's focus on RNA-based therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA therapy space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapies, targeting the same RNA-based therapeutic approach as Avidity.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.99B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, using RNAi technology similar to Avidity's approach.
Moderna
MRNA
Mkt Cap55.09B
Moderna is focused on drug discovery and drug development based on messenger RNA (mRNA), competing in the broader RNA therapeutics field.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech SE works on individualized cancer medicine and other diseases using mRNA technology, making it a competitor in the RNA-based therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is engaged in the development of gene-based medicines, including RNA-targeted therapies, placing it in competition with Avidity.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, indirectly competing in the genetic and RNA therapy space.

About

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Show more...
CEO
Kathleen Gallagher
Employees
511
Country
United States
ISIN
US04965N1046

Listings

BOATS
BOATS
RNA.BOATS
XNAS
US
RNA

0 Comments

Share your thoughts

FAQ

What is Atrium Therapeutics stock price today?▼
The current price of RNA is $14.60 USD — it has increased by +0% in the past 24 hours. Watch Atrium Therapeutics stock price performance more closely on the chart.
What is Atrium Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Atrium Therapeutics stocks are traded under the ticker RNA.
What is Atrium Therapeutics market cap?▼
Today Atrium Therapeutics has the market capitalization of 249.74M
When is the next Atrium Therapeutics earnings date?▼
Atrium Therapeutics is going to release the next earnings report on December 02, 2026.
What were Atrium Therapeutics earnings last quarter?▼
RNA earnings for the last quarter are -1.18 USD per share, whereas the estimation was -1.42 USD resulting in a +16.75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Atrium Therapeutics revenue for the last year?▼
Atrium Therapeutics revenue for the last year amounts to 37.51M USD.
What is Atrium Therapeutics net income for the last year?▼
RNA net income for the last year is -1.37B USD.
How many employees does Atrium Therapeutics have?▼
As of September 04, 2026, the company has 511 employees.
In which sector is Atrium Therapeutics located?▼
Atrium Therapeutics operates in the Health & Wellness sector.
When did Atrium Therapeutics complete a stock split?▼
Atrium Therapeutics has not had any recent stock splits.
Where is Atrium Therapeutics headquartered?▼
Atrium Therapeutics is headquartered in San Diego, United States.